Prognostic Clinicopathologic Factors in Longitudinally Followed Patients with Metastatic Small Bowel Carcinoid Abstract #28

Introduction: Neuroendocrine tumors demonstrate heterogeneous behavior based upon site of origin and specific histology. Even after controlling for anatomic location, disease stage and histologic grade, registry studies show persistent diversity of outcome in patients with midgut carcinoid.
Aim(s): This study aims to delineate prognostic clinicopathologic features in patients with metastatic small bowel carcinoid.
Materials and methods: A comprehensive neuroendocrine tumor database containing over 200 patients was used to identify cases of metastatic small bowel carcinoid managed at a tertiary care referral center from 1991 to 2007. All patients underwent primary tumor resection. Survival was measured from date of primary tumor resection and calculated by Kaplan-Meier estimation. When available, clinical data including age, sex, serum biomarkers, primary tumor size, Ki-67, and performance of hepatic cytoreductive procedure such as metastatectomy, ablation, or embolization were evaluated. Serially collected serum biomarkers were considered as mean values within time periods relative to primary resection: preoperative, 0-1 years postoperative and years 1 through 5 postoperative. Cox regression was applied to all variables with time dependent models used to assess prognostic value of biomarker change over time.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Mr. Thomas Curran

To read results and conclusion, please login ...

Further abstracts you may be interested in

#29 Serum chromogranin A correlation with tumor burden in metastatic small bowel carcinoid patients
Introduction: Patients with neuroendocrine tumors may have clinical courses that range from fairly indolent to more aggressive. Cross–sectional studies, nuclear imaging and biochemical markers are often used to monitor disease progression. Optimal surveillance tests and intervals have not been firmly established. Studies suggest that chromogranin A (CgA) may be a surrogate marker for tumor burden.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Mr. Thomas Curran
#1816 Multivisceral Transplantation and Vascularised Sentinel Forearm Flap for a Metastatic Small Bowel Neuroendocrine Tumour: Update on Follow-Up
Introduction: We previously reported the first documented case of a novel approach in a patient with extensive mesenteric metastases from a small bowel neuroendocrine tumour (SBNET): this combined multivisceral transplantation (MVT) and a vascularised sentinel forearm flap (VSFF) from the same donor.
Conference: 14th Annual ENETS conference (2017)
Category: Clinical cases/reports
Presenting Author: Anna Malczewska
Authors: Frilling A, Giele H, Vrakas G, Reddy S, ...
#1408 Epidemiological Factors at Diagnosis in a Large Cohort of Patients with Small Bowel Neurondocrine Tumours
Introduction: The incidence of small bowel Neuroendocrine Tumours (SBNETs) has been increasing. Despite previous reports, epidemiological data regarding several clinical factors are limited.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Dr Christos Toumpanakis
#1815 MicroRNAs Associated with Small Bowel Neuroendocrine Tumours and Their Metastases
Introduction: Novel molecular analytes are needed in small bowel NETs (SBNETs) to better determine disease aggressiveness and predict treatment response.
Conference: 14th Annual ENETS conference (2017)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Anna Malczewska
#375 How Long to Continue Surveillance in Patients Following ‘Curative Resection’ of Primary Small Bowel Tumors?
Introduction: Around 40-50% of patients with small bowel (SB) NETs have metastatic disease at the time of presentation. The majority of the remainder proceed to surgery for attempted curative resection. The optimal duration of surveillance post ‘curative surgical’ resection of primary SB NETs is unknown.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Raj Srirajaskanthan
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.